PharmacoEconomics (2017) 35:755–757 DOI 10.1007/s40273-017-0516-2 COMMENTARY Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling 1,2 3,4 Anthony J. Hatswell Fleur Chandler Published online: 20 May 2017 Springer International Publishing Switzerland 2017 In the recent National Institute for Health and Care being ethically superior by making better use of patient Excellence (NICE) appraisals for rheumatoid arthritis, the input. We will discuss each of these areas in turn, as well as six companies involved each independently conducted where collaboration is most likely to be advantageous. systematic reviews, economic modelling and network Should a model be developed collaboratively by multi- meta-analyses . Each will have incurred substantial ple companies, it would receive a much larger degree of agency fees and internal time to manage the projects. scrutiny. While this may take longer to achieve a ﬁnal Given the models were also based on a very similar version, it also means mistakes are less likely to survive the structure, each needed to solve very similar problems (in- process. With multiple companies also collaborating on dependently) from the perspective of disease progression. model design, the resulting model is also more likely to This is a typical situation, with examples ranging from
PharmacoEconomics – Springer Journals
Published: May 20, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera